

## **Product** Data Sheet

# **PROTAC EGFR degrader 7**


Cat. No.: HY-147858 Molecular Formula:  $C_{46}H_{48}N_{10}O_6$ Molecular Weight: 836.94

Target: PROTACs; EGFR; Apoptosis

Pathway: PROTAC; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Apoptosis

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.



## **BIOLOGICAL ACTIVITY**

Description	PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR <sup>L858R/T790M</sup> degrader, with a DC <sub>50</sub> of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC <sub>50</sub> of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research <sup>[1]</sup> . PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
IC <sub>50</sub> & Target	EGFR <sup>L858R</sup> /T <sup>790M</sup> 13.2 nM (DC50)
In Vivo	PROTAC EGFR degrader 7 (compound 13b) (BALB/c mice bearing NCI–H1975 cells, 10 mg/kg, IP, once a day for 24 days) effectively and selectively inhibits NCI–H1975 xenograft tumor growth, with the tumor growth inhibition (TGI%) of 63.7% <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### **REFERENCES**

[1]. Zhang W, et al. Discovery of highly potent and selective CRBN-recruiting EGFRL858R/T790M degraders in vivo. Eur J Med Chem. 2022 Aug 5;238:114509.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Inhibitors